Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody (Q81623742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Sharkey RM

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Karacay H

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Chang CH

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

McBride WJ

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Horak ID

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Goldenberg DM

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

1064-1069

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815716%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403751

10 January 2020

exact match

0 references

cites work

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403751

7 January 2021